Dianthus Therapeutics, Inc.

DNTH

NASDAQ

Healthcare

Biotechnology

New York City, NY, US78 employeesdianthustx.com

$86.51

+1.95(2.31%)

Mkt Cap $3.3B

$14.86

$86.92

52-Week Range

At a Glance

AI-generated

Dianthus Therapeutics, Inc.

Revenue breakdown: License (100%).

8-K

Dianthus Therapeutics, Inc. posted an updated corporate presentation on its website and disclosed FDA agreement to proposed changes in screening criteria and safety risk descriptions for ongoing and planned claseprubart trials, including removal of ANA testing and reclassification of SLE risk to DIL, with no cases observed to date.

$3.3B

Market Cap

$2M

Revenue

—

Net Income

Employees78

Fundamentals

How The Business Makes Money

Revenue by Segment

License100%($17M)

Activity

What Changed Recently

Material Agreement

Mar 11, 2026

Entry into a Material Definitive Agreement. On March 10, 2026, Dianthus Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting

Financial Results

Mar 8, 2026

Results of Operations and Financial Condition. On March 9, 2026, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s fin

Financial Results

Jan 11, 2026

, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,

Other Event

Mar 25, 2026

. In addition, in the first quarter of 2026, the Company proposed to the Food & Drug Administration ("FDA") the following changes to screening criteria and requ

Peer Companies

Company	Price	Change	Market Cap	P/E
ELVNEnliven Therapeutics, Inc...	$38.72	+2.45%	$2.3B	-16.8
ANABAnaptysBio, Inc.	$57.98	+2.20%	$1.7B	-131.7
NKTRNektar Therapeutics	$77.01	+1.72%	$1.6B	-9.2
OCSOculis Holding AG	$26.48	-2.03%	$1.5B	-11.0
IMTXImmatics N.V.	$10.36	+3.45%	$1.4B	-5.5
TRMLTRML	$47.98	+0.00%	$1.2B	—
TSHATaysha Gene Therapies, In...	$4.38	+1.74%	$1.1B	-13.3
SANASana Biotechnology, Inc.	$3.21	+5.08%	$855M	-3.2

Analyst View

Company Profile

CIK0001690585

ISINUS2528281080

CUSIP252828108

Phone929-999-4055

Address7 Times Square, New York City, NY, 10036, US

SEC EDGAR